LYRA (Lyra Therapeutics) Inventories, Raw Materials & Components: $0.00 Mil (As of Dec. 2025)


LYRA Lyra Therapeutics Inc LYRA
25 GF Score
Price $0.71
GF Value $2.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lyra Therapeutics Inventories, Raw Materials & Components?

Lyra Therapeutics LYRA +14.68% 25 Inventories, Raw Materials & Components is $0.00 Mil as of Dec. 2025. GuruFocus rates LYRA with a GF Score™ of 25/100 and a GF Value™ of $2.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

Lyra Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2025 was $0.00 Mil.

Lyra Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Lyra Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyra Therapeutics Inventories, Raw Materials & Components Chart

Lyra Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lyra Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LYRA
25GF Score
Lyra Therapeutics Inc LYRA
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyra Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?
Lyra Therapeutics (LYRA) has a Inventories, Raw Materials & Components of $0.00 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on Lyra Therapeutics and its competitors.
Is Lyra Therapeutics' Inventories, Raw Materials & Components too high?
Lyra Therapeutics' current Inventories, Raw Materials & Components is $0.00 Mil. Overall, Lyra Therapeutics has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' Inventories, Raw Materials & Components compare to EVFM and CLSDQ?
Lyra Therapeutics' Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Lyra Therapeutics and its competitors. Lyra Therapeutics's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.53, compared to a current price of $0.71 — trading 72% below its estimated fair value. The current Inventories, Raw Materials & Components is $0.00 Mil. Lyra Therapeutics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current Inventories, Raw Materials & Components is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyra Therapeutics (LYRA) Overvalued in 2026?

Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued. The current stock price of $0.71 is trading 72% below its estimated GF Value™ of $2.53. GuruFocus considers Lyra Therapeutics to be Possible Value Trap.

Key valuation signals for LYRA:

  • Inventories, Raw Materials & Components: $0.00 Mil
  • GF Value™: $2.53 vs. price of $0.71 (72% below fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyra Therapeutics Business Description

Address 480 Arsenal Way, Watertown, MA, USA, 02472
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
25GF Score

Get the complete analysis for LYRA

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price
$2.53
GF Value